Literature DB >> 30231226

Ivosidenib in IDH1-Mutated Acute Myeloid Leukemia.

Courtney D DiNardo1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30231226     DOI： 10.1056/NEJMc1809507

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  4 in total

Review 1.  Targeting Approaches of Nanomedicines in Acute Myeloid Leukemia.

Authors:  Xiao Huang; Hai Lin; Feng Huang; Yuning Xie; Ka Hong Wong; Xiaoyu Chen; Dongyue Wu; Aiping Lu; Zhijun Yang
Journal:  Dose Response       Date:  2019-12-11       Impact factor: 2.658

Review 2.  IDH1/2 mutations in acute myeloid leukemia.

Authors:  Ja Min Byun; Seung-Joo Yoo; Hyeong-Joon Kim; Jae-Sook Ahn; Youngil Koh; Jun Ho Jang; Sung-Soo Yoon
Journal:  Blood Res       Date:  2022-03-31

Review 3.  The contribution of single-cell analysis of acute leukemia in the therapeutic strategy.

Authors:  Lamia Madaci; Julien Colle; Geoffroy Venton; Laure Farnault; Béatrice Loriod; Régis Costello
Journal:  Biomark Res       Date:  2021-06-27

4.  Somatic IDH1 variant (p.R132C) in an adult male with Maffucci syndrome.

Authors:  Natasha J Brown; Zimeng Ye; Chloe Stutterd; Sureshni I Jayasinghe; Amy Schneider; Saul Mullen; Simone A Mandelstam; Michael S Hildebrand
Journal:  Cold Spring Harb Mol Case Stud       Date:  2021-12-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.